Literature DB >> 34159859

Unified exact design with early stopping rules for single arm clinical trials with multiple endpoints.

Wei Wei1, Denise Esserman1, Michael Kane1, Daniel Zelterman1.   

Abstract

Adaptive designs are gaining popularity in early phase clinical trials because they enable investigators to change the course of a study in response to accumulating data. We propose a novel design to simultaneously monitor several endpoints. These include efficacy, futility, toxicity and other outcomes in early phase, single-arm studies. We construct a recursive relationship to compute the exact probabilities of stopping for any combination of endpoints without the need for simulation, given pre-specified decision rules. The proposed design is flexible in the number and timing of interim analyses. A R Shiny app with user-friendly web interface has been created to facilitate the implementation of the proposed design.

Entities:  

Keywords:  Go/no go decisions; biomarker endpoints; conditional power; early phase; multiple endpoints

Mesh:

Year:  2021        PMID: 34159859      PMCID: PMC8959087          DOI: 10.1177/09622802211013062

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  27 in total

1.  Continuous toxicity monitoring in phase II trials in oncology.

Authors:  Anastasia Ivanova; Bahjat F Qaqish; Michael J Schell
Journal:  Biometrics       Date:  2005-06       Impact factor: 2.571

2.  A predictive probability design for phase II cancer clinical trials.

Authors:  J Jack Lee; Diane D Liu
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

Review 3.  Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials.

Authors:  Arif Manji; Irene Brana; Eitan Amir; George Tomlinson; Ian F Tannock; Philippe L Bedard; Amit Oza; Lillian L Siu; Albiruni R Abdul Razak
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

4.  Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials.

Authors:  P F Thall; H G Sung
Journal:  Stat Med       Date:  1998-07-30       Impact factor: 2.373

5.  BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints.

Authors:  Heng Zhou; J Jack Lee; Ying Yuan
Journal:  Stat Med       Date:  2017-06-07       Impact factor: 2.373

6.  Global cross-ratio models for bivariate, discrete, ordered responses.

Authors:  J R Dale
Journal:  Biometrics       Date:  1986-12       Impact factor: 2.571

Review 7.  Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.

Authors:  Rodrigo Dienstmann; Irene Braña; Jordi Rodon; Josep Tabernero
Journal:  Oncologist       Date:  2011-12-01

8.  Phase II trial design with Bayesian adaptive randomization and predictive probability.

Authors:  Guosheng Yin; Nan Chen; J Jack Lee
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2012-03-01       Impact factor: 1.864

9.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

10.  Admissible two-stage designs for phase II cancer clinical trials.

Authors:  Sin-Ho Jung; Taiyeong Lee; KyungMann Kim; Stephen L George
Journal:  Stat Med       Date:  2004-02-28       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.